Rituximab-immunoconjugate kit-formulations for NHL radioimmunotherapy

Smilkov, Katarina and Gjorgieva Ackova, Darinka and Gjorgoski, Icko and Janevik-Ivanovska, Emilija (2014) Rituximab-immunoconjugate kit-formulations for NHL radioimmunotherapy. Physioacta, 8 (2). pp. 113-120. ISSN 1857-5587

[img]
Preview
Text
Physioacta-sodrzina.pdf

Download (1445Kb) | Preview
[img]
Preview
Text
Physioacta-objaveno.pdf

Download (373Kb) | Preview

Abstract

Radioimmunotherapy (RIT) of Non-Hodgkin’s lymphoma (NHL) is said to be more advantageous compared to unlabeled therapeutic antibodies. To this date, radiolabelled murine anti-CD20 mAbs, Zevalin® and Bexxar® have been approved for imaging and therapy. A preparation containing rituximab, chimeric mAb immunoconjugate suitable for Lu-177 labeling, could provide better imaging and therapeutic profile at the same time. This study was conducted to evaluate prepared lyophilized formulations of three rituximab immunoconjugates, intended for immediate Lu-177 labeling, for imaging and therapy. The results showed preserved antibody structure and suitability for successful radiolabeling with over 95% radiochemical purity, encouraging further evaluation experiments.

Item Type: Article
Subjects: Medical and Health Sciences > Other medical sciences
Divisions: Faculty of Medical Science
Depositing User: Darinka Gorgieva Ackova
Date Deposited: 10 Mar 2015 11:17
Last Modified: 13 Mar 2015 12:49
URI: http://eprints.ugd.edu.mk/id/eprint/12886

Actions (login required)

View Item View Item